Indeed, our data shows a spread of FKBP5/1 expression (Figs. 1, 2) suggesting that for at least a subset of schizophrenia subjects, particularly those that are older, FKBP51 antagonism may present as an efficacious treatment approach with potential to ameliorate cognitive deficits via effects on dendritic spines as previously shown in cell cultures [41]. The gene discussed is FKBP5; the disease is schizophrenia.